The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02

The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).

Inclusion Criteria:

• Previously received and tolerated ALN-TTR02 (patisiran) in Study ALN-TTR02-002.
• Adequate Karnofsky performance status, liver function, and renal function.

Exclusion Criteria:

• Pregnant or nursing.
• Has had a liver transplant.
• Has a New York Heart Association heart failure classification >2.
• Has unstable angina.
• Has uncontrolled clinically significant cardiac arrhythmia.